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1. Introduction 
1.1 Renal transplantation 
Renal transplantation is the treatment of choice for most patients with end-stage renal 
diseases (ESRD). Patients usually undergo transplantation after a variable period of dialysis. 
Recently, due to development of standard surgical techniques and improvement in post 
transplantation care such as organ preservation, immunosuppressive and antimicrobial 
agents graft and patient outcome has significantly improved. The recognition of anti-donor-
HLA antibodies in a renal allograft recipient’s serum, at the time of or after transplantation, 
is usually correlated with specific antibody-mediated clinical syndromes which can be 
categorized into three groups such as hyperacute rejection, acute humoral rejection and 
chronic humoral rejection. Allograft rejection is caused by several component of the immune 
system; consist of antibody, complement, T cells and other cell types. The mechanisms of 
pathways of acute rejection are being determined and the consequences of immune rejection 
are identified by graft dysfunction and classified by histological features of allograft biopsy 
specimens (Solez et al., 2008).  
1.2 Hyperacute rejection 
Hyperacute rejection occurs within 24 hours of reperfusion and is characterized by immediate 
loss of graft function resulting abrupt cessation of urine flow. Hyperacute rejection might be 
either diagnosed clinically by the surgeon with mottling cyanosis and reduced turgor in the 
graft or by a histopathologic feature of interstitial hemorrhage, microthrombosis and 
inflammation (neutrophils and fibrin infiltration) of the failed allografts which might be 
qualitatively similar to those seen in acute antibody mediated rejection (AMR). Hyperacute  
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rejection is generally considered to be mediated by humoral immutnity (Baid S e al., 2001). 
Immunofluorescence (IF) studies demonstrated IgG (but not IgM) in glomerular and 
peritubular capillaries The pathogenesis of hyperacute rejection depends on the activation of 
complement activated through any pathway (classical, alternative, or lectin) can initiate 
hyperacute rejection regardless of how complement is activated (Chang A.T and Platt J.L. 
2009). Hyperacute rejection of clinical allografts is most often caused by anti-HLA antibodies 
which bind to blood vessels and activate the complement system in a newly transplanted 
organ. Hyperacute rejection is observed in up to 80% of the kidneys transplanted into 
recipients with cytotoxic antibodies detected by cytotoxic cross match (Patel R and Terasaki PI, 
1969). Hyperacute rejection is more common in allogarfts with these antibodies compared with 
ABO-incompatible renal transplants. Hyperacute rejection can also occur independent of anti-
donor antibodies and these cases may reflect activation of the alternative or lectin pathways as 
might occur with ischemic injury (Chang A.T and Platt J.L, 2009). 
Hyperacute rejection may occur in some recipients appearing to lack anti-donor antibodies. 
In some cases antibody capable of binding to and injuring the graft may be present but is 
not detected by assays in which leukocytes are used as the target. Fortunately, with the 
serologic technologies and expertise now available, hyperacute rejection has become an 
extremely rare occurrence. 
1.3 Acute rejection 
Acute rejection episodes (ARE) typically develop after transplantation at any time after 
organ transplantation and are divided histopathologically in to two categories: interstitial 
and vascular (Fig 1). A key clinical sign of acute rejection is a baseline rise in serum 
creatinine of 25% in the asymptomatic patient with no other apparent explanation.  Novel 
immunosuppressive drugs and regimens have decreased the incidence of acute rejection 
occurrence, however, acute rejection (AR) is still a major risk of early graft dysfunction and 
late kidney graft loss (kamali et al., 2009). Despite the introduction of successful 
immunosuppressive drug therapies, acute renal allograft rejection still occurs in 10–20% of 
patients after cadaveric renal transplantation and causes graft loss in up to 6% in the first 
year after transplantation (Magee, Pascual., 2004). The early phase of diagnosis of acute 
allograft rejection might help clinicians to perform required procedures to prevent 
undesirable posttransplant complications (kamali et al., 2009). 
1.3.1 Acute interstitial allograft rejection 
Also termed acute cellular rejection or acute reversible rejection is characterized by an 
infiltration of inflammatory cells (mainly of CD8 T lymphocytes) in the interstitium, and 
tubular epithelium involvement named tubulitis (Racusen LC et al. 1999).  Tubulitis has 
been regarded as a reliable marker for acute rejection even though it can be seen in other 
forms of interstitial nephritis (Colvin., 1996). The infiltrate is more concentrated in the cortex 
than in the renal medulla. Rejection that is predominantly cellular is considered to be readily 
reversible with therapy. 
1.3.2 Acute vascular rejection  
Acute vascular rejection is called as acute humoral rejection contains the most severe 
changes in the small arteries, veins, and arterioles. Humoral antibodies may cause tissue 
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injury or organ dysfunction by themselves or in collaboration with immunocompotent cells 
(Fig2) (Lederer S.R et al, 2001). The diagnostic criteria for acute humoral rejection are given 
in Table 1. 
1. Morphologic evidence of acute tissue injury 
acute tubular injury 
neutrophils and/or mononuclear cells in PTC 
and/or glomeruli and/or capillary thrombosis 
fibrinoid necrosis/intramural or transmural 
inflammation in arteries 
2. Immunopathologic evidence for antibody action 
C4d and/or (rarely) immunoglobulin in PTC 
Ig and complement in arterial fibrinoid necrosis 
3. Serologic evidence of circulating antibodies to 
donor HLA or other anti-donor endothelial antigen 
*Cases that meet only two of the three numbered criteria are considered suspicious for acute humeral 
rejection (AHR). Acute cellular rejection may also be present.  
Table 1. Diagnostic criteria for acute antibody-mediated rejection (adapted from Lorraine et 
al., 2006)* 
It is emphasized that humoral immune reactions soon after transplantation had a much 
stronger impact than alloreactivity during later periods. Occurrence of delayed graft function 
(DGF) was assumed as long-term consequences of alloreactivity events early after 
transplantation (Ojo et a.l, 1997). Humoral reactions late after transplantation that are clearly 
detectable in serum and biopsy samples obviously do not significantly reduce graft survival 
(Lederer et al., 2001).  In renal allograft recipients who experienced acute humoral rejection, 
donor-specific circulating alloantibody showed a sensitivity and specificity of 95% and 96% 
respectively (Feucht HE et al, 1991). Crespo and colleagues reported an acute rejection 
prevalence of 6.3% among 232 transplanted patients, two thirds of whom were steroid 
resistant (Crespo et a.l, 1999). Acute humoral rejection refractory to steroids and polyclonal 
antibodies leads to a 70% to 80% rate of graft loss (Watschinger B, Pascual M, 2002). The 
earliest morphologic characteristics of acute vascular rejection are swelling and vacuolization 
of the endothelial cells with areas of ulceration.  Graft survival among patients with acute 
humoral rejection and without specific therapy is poor but novel treatment modalities of acute 
humoral rejection has saved some grafts (Watschinger B, Pascual M, 2002). Acute humoral 
rejection therapy seeks to remove circulating antibodies through plasmapheresis or 
immunabsorption and to inhibit B-cell proliferation using mycophenolate. Acute humoral 
rejection requires different therapy than cell-mediated rejection. Therapy for Acute humoral 
rejection is plasmapheresis and intravenous Ig combined with intense immunosuppression 
(typically tacrolimus and mycophenolate mofetil). In analysis of 113 renal allograft recipients 
by Péfaur J. et al, the recipients received high doses of IVIG (2 g/kg in five doses; two also 
received plasmapheresis or thymoglobulin). Mycophenolate, tacrolimus, and steroids were 
used as maintenance immunosuppressive therapy. Patient and graft survivals were 100% 
(abapted from Péfaur J. et al, 2008). 
www.intechopen.com
 
Renal Transplantation – Updates and Advances 
 
104 
 
Fig. 1. (A) Acute cellular rejection (ACR): no staining for C4d is seen in peritubular 
capillaries. (B) Acute humoral rejection (AHR): widespread and bright staining for C4d is 
present in the peritubular capillaries that are interspersed in between the silhouettes of 
tubules. (C) ACR: mononuclear cells are present in the interstitium (*) and in peritubular 
capillaries (arrows). (D) AHR: abundant neutrophils are present in dilated peritubular 
capillaries (arrows). (E) ACR: scattered mononuclear cells are present in glomerular 
capillaries (arrows). (F) AHR: neutrophils are present in glomerular capillaries (arrows). 
Staining: C4d-FITC in A and B; Hematoxylin and eosin (H&E) in C, D, and F; and periodic 
acid-Schiff (PAS) in E. Magnifications: _400 in A through D; _450 in E and F. (adapted from 
Saadi et al. 2004) 
1.4 Antibody-mediated rejection 
As novel immunosuppressive protocols had effective control of T cell mediated acute 
rejection, antibody-mediated rejection (AMR) of renal allograft has re-emerged as an 
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important post-transplant complication.The complement system plays an important role in 
antibody mediated rejection (AMR) via classical pathway activation. Antibody-mediated 
rejection is characterized pathologically by focal ischemia, severe injury to the endothelial 
cells lining blood vessels in the graft and diffuse intravascular coagulation . 
Expression of anticoagulant molecules (thrombomodulin and heparan sulfate) from normal 
endothelial cells inhibit coagulation process (Miyata Y and Platt JL). Activated endothelial 
cells promote coagulation and inflammation which induce expression of cell adhesion 
molecules and cytokines (Saadi et al. 2004) 
1.5 Delayed graft function (DGF)  
Delayed graft function (DGF) and acute rejection are the two main early adverse events in 
renal transplantation. Historically, DGF was defined by the requirement for dialysis within 
the first week of renal transplantation. The rate of DGF varies between among different 
centers from 20 to 40% (Koning OH et al ,1997). The incidence of DGF was 20% to 29% 
among deceased donor kidneys and 6% among living donor kidneys (Halloran and 
Hunsicker, 2001). Investigation of 689 allograft renal transplants form HLA-mismatched 
unrelated living donors revealed the incidence of DGF was 7.7%, which was higher than 
reports with HLA-matched living related donors (Ghods AJ et al, 2007). Many pathological 
findings are associated with DGF, the most common being acute tubular necrosis. Typical 
histological findings of DGF are dilatation of tubules, loss of proximal epithelial cell brush 
border, epithelial cell necrosis/apoptosis, and cellular casts (Smith KD et al , 2003). The 
impact of DGF on long-term graft survival is controversial. Some, though not all, evidence 
suggests that DGF may increase the frequency of acute rejection and thus reduce long-term 
survival. Univariate and multivariate analyses showed that DGF significantly reduced the 
survival rate and half-life of renal grafts. Troppmann et al.  Found that only if DGF and early 
acute rejection co-existed would DGF be one of the risk factors that reduced the long-term 
survival rate of recipient kidney (Troppmann C et al. 1996).  The early inflammatory 
response is initiated by ischemia/reperfusion, activation of innate immunity and 
subsequent alloantigen-primed T cell recruitment, activation and proliferative expansion. 
DGF is also thought to up-regulate MHC class II antigens, thus predisposing the 
transplanted graft to an increased incidence of acute rejection, which can be recognized 
histologically by the presence of tubulitis and infiltration of leukocytes into the tubular 
epithelium (Daily P et al, 2005). However, there are also reports showing that DGF played a 
greater role as a risk factor than acute rejection and HLA mismatch, and that DGF affected 
renal graft survival by increasing acute rejection and the chronic rejection rate, and 
decreased the survival rate of renal graft independent of acute rejection (Geddes CC et al. 
2002). Aquino-Dias and associations have extended the diagnostic accuracy of mRNA 
profiles in recipients with DGF (Aquino-Dias EC. et al, 2008). Peripheral blood cell levels of 
TIM-3 mRNA are suspected to predict acute rejection in renal allograft recipients with DGF 
with a sensitivity of 100% and a specificity of 100% (Manfro RC et al, 2008).  The main 
modality in management of DGF is to support the patient with dialysis and to monitor for 
rejection with serial biopsies. 
At engraftment, ischemia-reperfusion injury occurs with activation of Toll-like receptors of 
the innate immune system and subsequent cytokine release. These pro-inflammatory 
mediators induce tubular epithelial cells to attract neutrophils and T cells by production of  
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Fig. 2. Diagram of postulated events leading to graft damage during kidney transplantation 
(Adapted from Womer K.L. and Kaplan B, 2009). 
chemokines. Innate immune system activation induces maturation of dendritic cells, leading 
the transition to the adaptive or antigen-specific phase of transplantation immunity. 
Dendritic cells activate CD4+ T helper cells through presentation of alloantigen in the 
context of major histocompatibility complex (MHC) molecules and ligation of appropriate T 
cell surface costimulatory molecules. After activation, CD4+ T helper cells induce further T 
cell proliferation, the production of alloantibodies from B cells, activation of macrophages, 
and differentiation of naïve CD8+ T cells into cytotoxic T lymphocytes. Mononuclear cells, 
especially cytotoxic T lymphocytes, enter between tubular cells and induce apoptosis by 
releasing cytolytic granules containing perforin and granzyme or by exposure to FasL on the 
T cell surface. Tubular cells chronically exposed to transforming growth factor ǃ (TGFǃ) 
may undergo epithelial-mesenchymal transition, an aberrant phenotype evidenced by 
epithelial cell expression of ǂ-smooth muscle actin and loss of E-cadherin expression. These 
cells then may migrate to the interstitium and contribute to fibrosis. Both T cells and 
antibody likely recognize alloantigen on target endothelium. While T cells may cause 
cytotoxicity directly, alloantibody is usually directed against the MHC molecule, followed 
by activation of complement. Antigen recognition leads to endothelial secretion of factors 
that activate the immune and coagulation systems. These activities promote rejection and 
chronic changes of the endothelium and underlying smooth muscle layer, resulting in the 
characteristic histopathologic findings of transplant arteriopathy. Alloantigen-independent 
factors also contribute to tubular and endothelial cell damage.  
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2. HLA matching  
The human leukocyte antigen system (HLA) is the name of the major histocompatibility 
complex (MHC) which contains a large number of genes related to immune system function 
in humans. This group of genes resides on chromosome 6 and encodes cell-surface antigen-
presenting proteins and many other proteins. HLA antigens on the cell membrane play an 
important role in the immune response to foreign tissue (Muczynski KA et al. 2003). HLA 
complex is highly polymorphous (Marsh SG et al. 2002). Thus it is difficult to identify none-
mismatched donors with only limited samples. In order to increase the matching rates, HLA 
typing has been recommended supported by the public epitope theory. MHC molecules are 
divided into 2 main classes: HLA class I antigens (HLA-A, HLA-B, HLA-C) are presented on 
the surface of all nucleated cells and platelets and HLA class II antigens (HLA-DR, HLA-
DQ, HLA-DP, HLA-DM, HLA-DO) are expressed on professional antigen-presenting cells, 
but also on the surface of endothelial vascular cells and renal tubular epithelial cells 
(Muczynski KA et al. 2003). Human capillary endothelial cells, in contrast to rodents, 
express both human lymphocyte antigen (HLA) class I and class II molecules with high 
density even under normal physiological conditions (McDouall RM. et al, 1997). Cytotoxic 
antibodies (anti-HLA) are not detectable normally but after the blood/plasma transfusion, 
in pregnancy or after a previous transplant. When these antibodies are directed against HLA 
system of transplanted organ, their targets are represented by the graft endothelial cells 
which is followed by activation of complement, coagulation cascade and other inflammation 
factors. This mechanism mediated by anti-HLA antibodies is called humoral rejection 
(hyperacute rejection) that results in severe injury of endothelial cells and dysfunction of the 
transplanted organ (Moise A et al 2010). The first clinical importance of anti-HLA antibodies 
was demonstrated in 1969 (Patel R and Terasaki PI. 1969). Now it is known that the 
recipients who present preformed cytotoxic antibodies have a high rate of graft rejection. 
Production of antibodies after transplantation remains the main factor of acute and chronic 
rejections. Sometimes, antibody-mediated rejection (AMR) is still inevitable in human 
leukocyte antigen (HLA)-identical donor-recipient transplants (Zou Y and Stastny P, 2009). 
Antibody sensitization to alloantigens of the HLA system is one of the greatest barriers in 
successful renal transplantation (Zou YZ et al. 2007). Moise and colleagues reported that in 
both, compatible and incompatible subjects, post-renal transplantation could develop de 
novo anti-HLA antibodies especially those had an HLA mismatch with donor predictable 
for acute graft rejection (Moise A et al 2010). HLA-I antigens can be identified on nucleated 
cells, including on the endothelia of small renal vessels. Anti-HLA-I Ig G antibodies can 
injure the small vascular endothelia of the graft and induce serious rejections such as HR 
(Halloran PF et al 1990, 1992). HLA-II antigens are mainly expressed by immune cells. It is 
previously accepted that HLA-II antibodies have a relatively minor impact on the early graft 
outcome, despite a few cases reported with a higher rejection rate and humoral rejections 
occurrence due to HLA-II antibodies. A large-scale multi-center clinical study illustrated 
that graft survival rate at two or three years was decreased in recipients with both HLA-I 
and HLA-II antibodies, this was lower in recipients with more than three mismatched HLA 
alleles (Susal C and Opelz G. 2004). However, no significant difference was found in 
recipients with HLA-II antibodies compared with unsensitized patients. It is suggested that 
ELISA detected development of HLA antibodies, especially HLA-I antibodies, in the post-
transplant period may provide a good predictor of acute rejection and of graft survival. 
Besides according to tissue inflammation and repair mechanisms inflicted by anti-HLA 
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antibodies results in exposure of self antigens which lead to post-transplant autoimmunity. 
Detection of immune responses to self-antigens will provide new strategies to monitor and 
prevent development of late graft dysfunction (Natha DS. et al, 2010).  
3. Immunologic factors in renal transplantation 
A major challenge for the field of transplantation is the lack of understanding of molecular 
mechanisms of immune response early after transplantation. The association between the 
presence of donor specific antibodies (DSA) and acute rejection has been noted in the late 
1970s (Hartono C et al. 2010). Complement proteins have been described to play a significant 
role in organ damage following transplantation both in the process of ischemia reperfusion 
and in modulating the activation of the adaptive immune response. Based on the knowledge 
alloreactive T cells are key mediators of transplant injury (Dinavahi R. et al, 2008). It has 
become clear that the type of specific immune response to offending agents is largely 
dependent on the preferential activation of peculiar CD4ı T helper (Th) cells able to secrete 
defined patterns of cytokines. Two distinct CD4ı T helper cell subsets, coded as Th1 and Th2, 
showing distinct and mutually exclusive patterns of cytokine secretion, have been identified in 
both mice and humans (Romagnani S. et al, 1995). Significant efforts have been carried out to 
demonstrate methodologies that reliably measure cellular alloimmunity, and in determining 
the utility of these approaches as biomarkers for acute rejection, biopsy proven fibrosis and 
impaired allograft function. Traditional methods of measuring T cell alloreactivity include 
proliferation and cytotoxicity assays, performed either on bulk cultures (mixed lymphocyte 
responses) or as limiting dilution assays. While these methods are accepted as useful research 
tools, their intensive labor requirements and limited reproducibility have prevented them 
from becoming standardized clinical tests (Dinavahi R. et al, 2008). 
4. Serum markers of allograft dysfunction 
Identification of serum markers or parameters before and after transplantation of recipients 
assuming increased risk of allograft rejection helps clinicians for a successful performance in 
individualization of immunosuppression therapeutic regimens and ensures a more 
adequate follow-up of these patients (Rouschop KM et al, 2005). High dose 
immunosuppression should be avoided at least for low-risk recipients due to the massive 
side effects such as cancer development, infection and toxicity. For example, Aggressive 
immunosuppression may reactivate polyoma BK virus, which is usually latent in the 
urinary tract.  Few biologic assays that might be potentially useful for monitoring the 
immune status of renal graft recipients have been reported (Susal C et al. 2003). Some 
reports have elucidated that a number of acute-phase reactants, such as C-reactive protein 
(Oyen O et al, 2001) and pro-inflammatory cytokinesn (IL-6), have been associated with 
allograft rejection (Waiser J et al, 1997), although their usefulness also has been debated 
(Cueto-Manzano et al, 2005). It is noted that IL-17 may be involved early alloimmune 
response during the course of acute rejection. IL-17 may play the role of an early initiator of 
the T cell-dependent inflammatory reaction. Human IL-17, a new cytokine secreted from 
CD4+ activated memory T cells, can stimulate the production of proinflammatory and 
haematopoietic cytokines by macrophages and stromal cells (Fossiez F et al, 1996). 
Immunofluorescence has shown the expression of IL-17 in kidney biopsies from patients 
suffering from graft rejection, while pretransplant biopsies and normal kidneys were  
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negative. Recently, monocyte-associated IL-18 has been suggested to be a pertinent 
biomarker in keeping with growing interest in monocyte infiltration during rejection.  Striz 
et al. also observed a significant increase in serum IL-18 levels in patients with acute renal 
allograft rejection, compared with patients with uncomplicated transplantation, and further 
showed that IL-18 mRNA was released in response to increased TNF-_ and IFN-_ 
production (Striz I et al, 2005). Another complement component which has important role in 
organ transplantation is CD55, which is also called  Decay Accelerating Factor (DAF). This 
molecule is present on the cell surface e where it accelerates the decay of C3 and C5 
convertases from the classic and alternative pathway of complement to prevent their 
amplification and self-damaging effect on cells (Medof ME. et al, 1984).  Early post-
transplant acute rejection and infection are major causes of morbidity and mortality, 
whereas, lack of full rehabilitation, drug toxicity, chronic rejection and malignancies 
constitute debilitating the long-term complications. All problems described above may be 
(directly or indirectly) related to the lack of easy and feasible immunological tests for 
predicting the risk of rejection and recognizing ongoing rejections after transplantation as 
early as possible. (Truong DQ. et al, 2007). It has long been a goal of transplant 
immunologists to develop tests for assessing the pretransplant risk of patients for 
immunologic rejection and for recognizing impending rejections after transplantation as 
early as possible (Susal C. al, 2004).  
5. Soluble CD30 (sCD30) 
In addition to cytokines, other relevant proteins have been studied. Soluble CD30 (sCD30), a 
member of the TNF receptor superfamily that is a 120 kD membrane glycoprotein and 
expressed on Th2 cells, may be useful. (Serum levels of sCD30 are associated with disease 
activity of Th2-type cells and with disease remission in Th1-mediated disease states. Although 
the role of Th1 versus Th2 responses in allograft rejection has been strongly debated, CD30_ T 
cells are implicated in the alloimmune response (Martinez OM et al, 1998).  
Recent reports have proposed sCD30 as a noninvasive serological marker to predict 
immunological risk and graft failure among kidney transplant recipients (Pelzl S. et al, 
2003). Both CD4 and CD8 T cells expressed CD30 after primary alloantigenic stimulation 
(Martinez OM. et al, 1998). Th1 cytokines including IL-2, TNF-ǂ, and IFN-Ǆ mediate cellular 
immune responses and are pro-inflammatory, whereas, Th2-type cytokines IL-4 and IL-10 
have been shown to inhibit the development and function of Th1-cells, to suppress 
inflammation, and to enhance humoral pathways of the immune response (Warle Mc. et al, 
2001). Some studies suggested that CD30 may serve as a marker for human T lymphocytes 
that produce Th2 cytokines (Manetti R. et al, 2007), while others demonstrated a strict 
association between CD30 expression and Th1 cytokine production (Martinez OM. et al, 
1998). However, Pellegrini et al. found that CD30 may be an important co-stimulatory 
molecule and marker for the physiological balance between Th1/Th2 immune response 
(Pellegrini P. et al, 2003). After activation of CD30+ T cells, a soluble form of CD30 (sCD30) 
is released proteolytically, however, the biological significance of this process is still not 
clearly defined (Dong W. et al, 2006). Th1-cytokines are mainly involved in allograft 
rejection, while Th2-type immune response may be graft protective by blocking the graft 
damaging Th1-type anti-donor response (Reding R. et al, 2006). A soluble form of CD30 
(sCD30) is released into the bloodstream after activation of CD30+ T cells (Romagnani S. et 
al, 1995). 
www.intechopen.com
 
Renal Transplantation – Updates and Advances 
 
110 
5.1 Pre transplant CD30 
Several reports from the Collaborative Transplant Study (CTS) have suggested that elevated 
pre and post-transplantation levels of the soluble CD30 (sCD30) molecule might be 
predictive for an increased incidence of rejection and worse kidney graft prognosis (Sengul 
S et al 2006). 
Many reports have supported a role for sCD30 in the immune response associated with 
renal allograft rejection. The presence of increased pretransplantation concentrations of 
sCD30 has been associated with the development of acute rejection (Langan LL et al. 2007) 
and with humoral rejection and graft loss. While some reports demonstrated that T-cell 
activation marker soluble CD30 (sCD30) was an independent predictor of immunologic risk 
in renal transplant recipients without preformed alloantibodies (Vaidya S et al. 2006). It was 
reported that high sCD30 levels measured before transplantation, which might be a sign of 
activation of Th2 responses and, consequently, antibody production, could correlate with 
the risk of vascular rejection and production of DSA (Weimer R. et al, 2006). However lower 
levels of sCD30 was determined to be a helpful marker to distinguish patients with a low 
risk for development of DSA and antibody-mediated rejection (Slavcev A. et al, 2007). Study 
by Vaidya et al. recognized that estimation of sCD30 before transplantation might be a 
better predictive factor than PRA for the evaluation of the risk for occurrence of DSA and 
development of vascular rejection (Vaidya S et al. 2006). Some authors described an 
increased sCD30 level only during a rejection episode of the vascular type, while the more 
common tubulointerstitial type showed decreased sCD30 levels even lower than those of 
healthy volunteers (Rajakariar R. et al, 2005). According to some studies the sCD30 
concentration was also high in both groups of patients before transplantation and levels of 
sCD30 decreased during the first 3 to 5 posttransplant days, increasing significantly between 
5 and 15 days following transplantation among recipients who developed acute rejection 
episodes (Ayed K et al. 2006). Measurements of serial changes in soluble CD30 levels after 
transplantation have revealed a decrease of sCD30 in stable transplant recipients (Sengul S 
et al 2006).  Kamali and colleagues have measured Pre and post-operative sCD30 levels of 3 
groups (acute rejection, delayed graft function, and uncomplicated course group). It has 
been described significant decreases in sCD30 plasma levels on 14th day after transplant. 
Despite a significant decrease, groups of patients with acute rejection had higher CD30 
concentrations on the 14th day after the transplants, compared with delayed graft function 
and uncomplicated course groups (Kamali K. et al, 2009). Based on published results pre-
transplant sCD30 serum levels higher than 100 U/ml have been classified as a risk factor for 
the survival of kidney allografts (Cinti P. et al, 2005).  In a large series of nearly 3900 kidney 
transplants performed at 29 centers in 15 countries, it was demonstrated that pretransplant 
determination of the Th2-type activation marker sCD30 is a powerful indicator for 
estimating the risk of graft rejection not only in presensitized but also in nonsensitized 
recipients (Susal et al. 2002). Patients with history of renal transplantation had higher levels 
of s CD30 than first kidney graft recipients (Susal et al. 2002). Investigation of pretransplant 
serum sCD30 content in 2998 recipients with a low sCD30 of <100 U/ml demonstrated a 
higher a 5-yr graft survival rate compared with 901 recipients with a high sCD30 of >100 
U/ml. Determination of the sensitivity and specifity sCD30 testing based on positive 
(≥100U/ml) and negative (<100 U/ml) levels has revealed that with a specificity of sCD30 
>80%, negative sCD30 levels might be a useful marker for identifying patients with a low 
risk for development of donor specific  antibody (DSA) and antibody-mediated rejection 
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(Slavcev A. et al, 2007). Spiridon C and associates found  no statistically significant difference 
among patients with 3–6 HLA-A, B, DR mismatches and 0–2 HLA-A, B, DR mismatches when 
pre-transplant level of sCD30 was below 90 U/mL. It is indicated that the effect of HLA 
mismatches can only be seen among patients with high level of sCD30 (Spiridon C. et al, 2008). 
Correlation between serum levels of sCD30 and Neopterin, which is a known activation 
marker of the T-cell/monocyte system and plays an important role in the chronic allograft 
nephropathy (CAN) process, demonstrated that up-regulation of 1-year sCD30 levels was 
associated with decreased 2-year GFR (. It was observed that increased 1-year sCD30 as well as 
Neopterin/CR are significantly associated with impaired 2-year graft function and serve as 
indicators of graft deterioration by chronic allograft nephropathy (Weimer R. et al, 2006). 
Association of sCD30 levels and immunosuppressive regimen has also been investigated. 
Pretransplant sCD30 assessment may serve as a useful parameter because high pretransplant 
sCD30 levels were shown to be associated with impaired kidney graft survival in 
Cyclosporine-A treated recipients (Susal C. et al, 2002). The current prospective randomized 
study shows that both cyclosporine-A and Tacrolimus based immunosuppressive regimens, 
used either in combination with  Azathioprine or mycophenolate mofetil (CellCept), were 
associated with down-regulation of pretransplant sCD30 levels 4 months post-transplant, 
without a further significant change from 4 months to 1 and 2 years. It was demonstrated that 
Tacrolimus based regimens are more effective in suppressing sCD30 levels and thus might be 
the appropriate treatment in patients with pretransplant elevated sCD30. It was found an 
association between CD4 helper function and sCD30 2 years post-transplant, both in 
Cyclosporine-A and Tacrolimus treated patients, which might be the result of diminished 
suppression of CD4 helper activity due to reduced Calcineurin inhibitor drug exposure 
(Weimer R. et al, 2000). This evidence suggests that the measurement of sCD30 levels offers 
relevant clinical information regarding rejection risk and can contribute to the selection of the 
appropriate immunosuppressive regimen in high-risk recipients for the prevention of acute 
rejection and chronic allograft nephropathy (Kim MS et al. 2006). 
5.2 Post transplant CD30 
To prevent irreversible graft damage, it is important to diagnose and treat acute rejection in 
its earliest phase. Serial measurement of sCD30 levels after transplantation could become a 
feasible and non invasive method to predict acute graft rejection and might allow 
identifying patients prone to acute rejection during the first days after transplantation; 
before an acute rejection was occurred and diagnosed by conventional methods. 
Importantly, at this early time point, detection of acute rejection in the kidney with DGF is 
made difficult because conventional noninvasive rejection parameters, such as rising serum 
creatinine and oliguria cannot be used to make the diagnosis, however, sCD30 allowed a 
differentiation of group acute rejection from group DGF patients (Dong W. et al, 2006). In 
contrast to patients with an uncomplicated course or acute tubular necrosis (ATN) in the 
absence of rejection, plasma sCD30 levels remained high during the first 3 to 5 
posttransplant days in recipients who subsequently developed acute allograft rejection 
(Susal C. et al, 2004). Now it is clear that the sCD30 levels decrease significantly after renal 
transplantation. It was reported that even in patients developed kidney rejection sCD30 
levels decreased up to 55% at day 7 post-transplantation (Truong DQ. et al, 2007). In a 
similar study, showed that an important decrease of sCD30 was detected 2 weeks after renal 
transplantation and patients without rejection had lower sCD30 value compared to patient 
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who experienced rejection episodes (Slavcev A. et al, 2005). Comparison of CD30 
concentrations on the 14th day after transplantation, within acute rejection, delayed graft 
function (DGF) and uncomplicated course groups revealed that a higher soluble CD30 
concentration on day 14 after transplant is associated with acute rejection (Kamali K. et al, 
2009). In sera of 231 patients average sCD30 level before transplantation was much higher 
than that of healthy individuals. Most important, the decrease of sCD30 levels after 
transplantation varied in different groups. Compared with Group UC and DGF, patients of 
Group acute rejection had higher sCD30 levels on day 5 posttransplantation. Data also show 
that there was no association between rejection time and sCD30 levels (Dong W. et al, 2007). 
It is demonstrated that patients free of rejection in the first month post-transplant had lower 
sCD30 concentrations 2 weeks after transplantation compared to rejecting patients (Slavcev 
A. et al, 2005). Thus, an integration of the individualized evaluation of posttransplant sCD30 
serum level as one biomarker, together with accompanying diseases which affect the 
immunological reactivity post-transplantation, may be a feasible approach for the non-
invasive post-transplant prediction of acute kidney allograft rejection. 
6. Panel-reactive antibody (PRA) 
Renal transplantation in sensitized patients remains a highly significant challenge 
worldwide. However, highly sensitized candidates should not be eliminated from 
transplant waiting lists, as post-transplant survival rate and life quality can be greatly 
improved with transplantation, despite the risks. The level of sensitization in a kidney 
transplant recipient can be monitored before and after renal transplantation via PRA (panel-
reactive antibody) test. Highly sensitized recipients usually refer to those with antibodies 
against HLA, who are defined as panel reactive antibody (PRA) >10%, or >20%. The 
humoral immune system is an important determinant of outcome: hypersensitized patients 
show reduced long term graft survival and 10% panel reactive antibodies (PRA) is a risk 
factor (Davis CL, 2004 and Opelz G, 2001). Thus elevated panel reactive antibody (PRA) 
levels, produced against HLA and induced by transfusions, pregnancies and prior 
transplants for HLA allo-immunization are linked to hyper-acute rejections, delayed graft 
functions and poor graft survival rates. Measurement of anti-HLA antibodies before and 
after transplantation is important, as their presence increases the risk and severity of 
rejection episodes and is a significant risk factor for allograft loss (Zhou YC. et al, 1996). 
During past years, transplant surgeons usually focused on the results of PRA levels and 
lymphocyte toxicity test in the treatment of sensitized patients, but sometimes serious 
antibody mediated rejections also happened in HLA-identical donor-recipient transplants. 
Although we have not yet confirmed whether there are any anti-HLA antibodies not well 
detected with existing technologies, the concept of non-HLA antibodies bring the transplant 
surgeons and researchers with great inspiration. Following the more recent development of 
ELISA methodology for detecting HLA antibodies, several reports showed that patients 
with pretransplant HLA-I antibodies (>10% PRA) had greater risk for acute or chronic 
rejection, or an increase in post-transplant reactivity (Van Kampen CA. et al, 2001). It was 
observed a higher incidence of post-transplant donor specific HLA antibodies in patients 
having 3–50% PRA compared with patients having 0% PRA at the time of transplantation 
(Supon P. et al, 2001). The determination of panel reactive antibodies, which at present are 
exclusively used as indicators for an increased risk of graft rejection, is currently being 
critically discussed. It is illustrated that combination of positive PRA and elevated sCD30 
www.intechopen.com
 
Soluble CD30 and Acute Renal Allograft Rejection 
 
113 
levels have an additional diagnostic value,  as well as independent factors, to predict  acute 
rejection risk and subsequent graft outcome (Langan L L. et al, 2007). For this reason novel 
markers are recommended for proper monitoring of pre- and post-transplant risks. Using 
the modalities described, immunosuppressive therapies in transplant recipients can now be 
selected on the basis of individual demand, with anti-B-cell directed immunosuppression 
being most promising during the early postoperative period.  
7. Immunosuppressive therapy 
The influence of immunosuppressive regimens on sCD30 levels was provoked in many 
studies. Presensitized (PRA >5%) patients had a higher serum sCD30 content than 
nonsensitized (5% >PRA) patients. whereas, as shown in Figure 3, the effects of the two 
parameters on graft outcome were additive. Therefore presensitized patients are 
preferentially transplanted with HLA well-matched kidneys and receive stronger 
posttransplant immunosuppression, including prophylactic treatment with antilymphocyte 
antibodies (susal et at. 2002). Immunosuppressive treatment in recipients usually contains 
either with a triple drug regimen (Cyclosporine, Steroids and Azathioprine) or, in 
Presensitized patients with immunologic risk factors (presence of panel-reactive antibodies 
or history of graft rejection), a quadruple regimen, including polyvalent or monoclonal 
antilymphocyte antibodies. When patients were divided into well-matched group (with 
three or less mismatches) and poor-matched group (with more than three mismatches), no 
significant difference of sCD30 levels was shown between two groups. Soluble CD30 levels  
 
(Adapted from susal et at. 2002) 
Fig. 3. Combined effect  of serum sCD30 content and lymphocytotoxic panel reactivity 
(PRA) on kidney graft survival. sCD30- positive and PRA-positive recipients 
(sCD30+/PRA+) had a significantly impaired graft outcome, compared with sCD30-negative 
and PRA-negative (sCD30_/PRA_), sCD30-negative and PRA-positive (sCD30_/PRA+), or 
sCD30-positive and PRA negative recipients (sCD30+/PRA_) (P < 0.0001, P = 0.0003, and  
P = 0.0048, respectively). 
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were also independently evaluated in patients receiving cyclosporine A and FK506. There 
was also no significant difference of sCD30 levels between two groups. Significant 
difference of sCD30 levels was only observed between patients with acute rejection episodes 
and those without acute rejection on day 5 post-transplantation (Dong W. et al, 2006). 
Antithymocyte globulin (ATG) is recommended for desensitization of kidney transplant 
recipients with high panel-reactive antibody (PRA) and ABO-incompatibility as main 
modality for the treatment of AMR (Akalin E. et al, 2003 and Gloor JM. et al, 2003).  But 
antilymphocyte antibodies did not improve graft outcome in patients with high sCD30. 
Graft survival of recipients with a high pretransplant sCD30 treated with prophylactic 
antilymphocyte antibodies (ATG, ALG, or OKT3), was significantly worse than the rate in 
recipients with low sCD30 levels.  It is suggested that a single dose of Rituximab (50 mg/m2 
BSA) is as effective as higher doses (150 and 375 mg/m2 BSA) in depleting Bcells and 
reducing PRA levels, While the standard dose of Rituximab in AMR is 375 mg/m2 BSA 
(Vieira CA. et al, 2004). Thus, to improve graft outcome in patients with high sCD30 levels, 
other strategies seem to be necessary, possibly immunosuppressive regimens that 
specifically inhibit CD30+ T cells. 
8. Conclusion 
It is illustrated that combination of positive PRA and elevated sCD30 levels have an 
additional diagnostic value,  as well as independent factors, to predict  acute rejection risk 
and subsequent graft outcome. For this reason novel markers are recommended for proper 
monitoring of pre- and post-transplant risks. This evidence suggests that the measurement 
of sCD30 levels offers relevant clinical information regarding rejection risk and can 
contribute to the selection of the appropriate immunosuppressive regimen in high-risk 
recipients for the prevention of acute rejection and also chronic allograft nephropathy.  
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